FDA, seeking time for phase 4 talks, delays decision on Valneva's chikungunya vaccine by 3 months

The FDA is making Valneva wait. Two weeks from the original deadline, the agency has pushed back its decision on whether to approve Valneva’s chikungunya virus vaccine candidate by three months.